[go: up one dir, main page]

AR008355A1 - COMPOSICIoN FARMACÉUTICA PARA ADMINISTRACIoN ORAL, USO, CREMA FARMACEUTICA PARA ADMINISTRACIoN TOPICA Y SUSPENSIoN LIQUIDA PARA ADMINISTRACIoN ORAL. - Google Patents

COMPOSICIoN FARMACÉUTICA PARA ADMINISTRACIoN ORAL, USO, CREMA FARMACEUTICA PARA ADMINISTRACIoN TOPICA Y SUSPENSIoN LIQUIDA PARA ADMINISTRACIoN ORAL.

Info

Publication number
AR008355A1
AR008355A1 ARP980102114A ARP980102114A AR008355A1 AR 008355 A1 AR008355 A1 AR 008355A1 AR P980102114 A ARP980102114 A AR P980102114A AR P980102114 A ARP980102114 A AR P980102114A AR 008355 A1 AR008355 A1 AR 008355A1
Authority
AR
Argentina
Prior art keywords
oral administration
pharmaceutical composition
administration
pharmaceutical
liquid suspension
Prior art date
Application number
ARP980102114A
Other languages
English (en)
Original Assignee
Romark Lab Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/887,810 external-priority patent/US5856348A/en
Priority claimed from US08/887,809 external-priority patent/US5965590A/en
Application filed by Romark Lab Lc filed Critical Romark Lab Lc
Publication of AR008355A1 publication Critical patent/AR008355A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composicion farmacéutica que contiene como agente activo por lo menos un compuesto seleccionado del grupo integrado de la formula (I), y la formula(II). El agente activo tiene preferentemente la forma de partículas con un tamano de partícula menorque 200 micrones y un tamano medio de partículamayor que 10 micrones. De manera preferente, la composicion farmacéutica está estabilizada con por lo menos un ácido farmacéuticamente aceptable, esutil para el tratamiento de infeccio nes oportunistasen personas con el sistema inmune comprometido o suprimido, así como en el tratamiento de infecciones por tremátodos.
ARP980102114A 1997-05-07 1998-05-07 COMPOSICIoN FARMACÉUTICA PARA ADMINISTRACIoN ORAL, USO, CREMA FARMACEUTICA PARA ADMINISTRACIoN TOPICA Y SUSPENSIoN LIQUIDA PARA ADMINISTRACIoN ORAL. AR008355A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/852,447 US5968961A (en) 1997-05-07 1997-05-07 Pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,810 US5856348A (en) 1994-09-08 1997-07-03 Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,809 US5965590A (en) 1994-09-08 1997-07-03 Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide

Publications (1)

Publication Number Publication Date
AR008355A1 true AR008355A1 (es) 2000-01-19

Family

ID=25313357

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102114A AR008355A1 (es) 1997-05-07 1998-05-07 COMPOSICIoN FARMACÉUTICA PARA ADMINISTRACIoN ORAL, USO, CREMA FARMACEUTICA PARA ADMINISTRACIoN TOPICA Y SUSPENSIoN LIQUIDA PARA ADMINISTRACIoN ORAL.

Country Status (11)

Country Link
US (2) US5968961A (es)
AR (1) AR008355A1 (es)
BG (1) BG65679B1 (es)
CO (1) CO4950538A1 (es)
CU (1) CU23318A7 (es)
ID (1) ID24828A (es)
LT (1) LT4751B (es)
PL (1) PL193556B1 (es)
RO (1) RO122247B1 (es)
RS (2) RS49831B (es)
ZA (1) ZA983849B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
CA2467321A1 (en) * 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US20070015803A1 (en) * 2005-04-12 2007-01-18 Romark Laboratories L.C. Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
ES2422556T3 (es) 2006-01-09 2013-09-12 Romark Lab Lc Tratamiento de hepatitis vírica
JP5726766B2 (ja) 2009-02-13 2015-06-03 ロマーク ラボラトリーズ エル．シー． ニタゾキサニドの制御放出医薬配合物
KR101760956B1 (ko) 2009-05-12 2017-07-24 로마크 레버러토리즈, 엘.씨. 할로알킬 헤테로아릴 벤즈아미드 화합물
BRPI1014322A2 (pt) 2009-06-26 2015-08-25 Romark Lab Lc Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
JP6138764B2 (ja) 2011-05-16 2017-05-31 ロマーク ラボラトリーズ エル．シー． ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用
EP2808019B1 (en) * 2012-01-27 2019-09-25 Siegfried Rhein S.A. De C.V. Improved nitazoxanide composition and preparation method thereof
US20140306689A1 (en) 2013-04-10 2014-10-16 Texas Instruments, Incorporated High resolution current pulse analog measurement
JP6633092B2 (ja) 2014-11-11 2020-01-22 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法
CN108289961A (zh) 2016-03-31 2018-07-17 罗马克实验室有限公司 用于治疗病毒性感染的噻唑化物化合物
DK3442580T3 (da) 2016-04-11 2020-12-21 Genfit Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme
WO2018195035A1 (en) 2017-04-18 2018-10-25 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase a3
KR20200121816A (ko) 2018-02-02 2020-10-26 리플 테라퓨틱스 코포레이션 스테로이드 이량체를 포함하는 유리 제제 및 이의 용도
WO2019241376A1 (en) 2018-06-14 2019-12-19 The Trustees Of Columbia University In The City Of New York Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
WO2020154815A1 (en) 2019-02-01 2020-08-06 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
US20220347305A1 (en) 2019-08-07 2022-11-03 Ripple Therapeutics Corporation Controlled release drug dimers
CA3176134A1 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
JP2023537237A (ja) 2020-07-20 2023-08-31 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニドおよび２－ヒドロキシ－ｎ－（５－クロロ－１，３－チアゾル－２－イル）ベンズアミド（ｒｍ－４８４８）とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびｎ－メチルピペラジンの結晶塩
CN116367892A (zh) 2020-08-24 2023-06-30 罗马克实验室有限公司 噻唑化物抗冠状病毒的用途
GB2625684A (en) 2021-10-05 2024-06-26 Council Of Scient And Industrial Research An Indian Registered Body Incorporated Under The Regn Of S An improved process for the preparation of nitazoxanide and intermediates thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US4315018A (en) * 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5496809A (en) * 1989-05-10 1996-03-05 Bristol-Myers Squibb Co Stable solutions of rebeccamycin analog
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
HUT77404A (hu) 1994-04-13 1998-04-28 Jean-Francois Rossignol N-(5-nitro-2-tiazolil)-benzamid-származékok és az ezeket tartalmazó gyógyszerkészítmények

Also Published As

Publication number Publication date
PL193556B1 (pl) 2007-02-28
YU57199A (es) 2002-08-12
ZA983849B (en) 1999-08-27
ID24828A (id) 2000-08-24
CO4950538A1 (es) 2000-09-01
RS50046B (sr) 2008-11-28
CU23318A7 (es) 2008-10-22
LT99141A (en) 2000-08-25
BG65679B1 (bg) 2009-06-30
US5968961A (en) 1999-10-19
US6117894A (en) 2000-09-12
RS49831B (sr) 2008-08-07
LT4751B (lt) 2001-01-25
RO122247B1 (ro) 2009-03-30
RS20070379A (sr) 2008-06-05

Similar Documents

Publication Publication Date Title
AR008355A1 (es) COMPOSICIoN FARMACÉUTICA PARA ADMINISTRACIoN ORAL, USO, CREMA FARMACEUTICA PARA ADMINISTRACIoN TOPICA Y SUSPENSIoN LIQUIDA PARA ADMINISTRACIoN ORAL.
ES2193726T3 (es) Formulaciones de aerosol medicinales.
AR018109A1 (es) FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
MX9304530A (es) Suministro topico mejorado de farmacos.
ES2137350T3 (es) Formulacion farmaceutica.
SE8705043D0 (sv) Hydrosols of pharmacologically active agents and their pharmaceutical compositions comprising them
DK1582204T3 (da) Echinocandin-farmaceutiske formuleringer, der indeholder miceldannende overfladeaktive stoffer
ATE321532T1 (de) Pharmazeutische zubereitungen und verfahren zu deren lokalen verabreichung
AR038575A1 (es) Formulacion oftalmica con nueva composicion de goma
RU2014114221A (ru) Композиции и способы доставки фармакологических агентов
BR9913945A (pt) Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
ATE85757T1 (de) Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung.
ATE311904T1 (de) Halbfester verabreichungsträger und arzneimittel
AR006087A1 (es) Forma de dosificación para la administración de clorhidrato de verapamil a una velocidad de liberación uniforme.
GB2334446A (en) Aqueous compositions compromising a lipid and a lanolin-derived surfactant,and their use
BR9913135A (pt) Formulação oral
LV12492A (en) Pharmaceutical compositions of tizoxandine and nitazoxanide
SE9704400D0 (sv) Porous inorganic particles as carriers for drug substances
KR950007857A (ko) 경구투여용 라파마이신 제제
ES2128353T3 (es) Composicion topica que contiene penciclovir.
BR9806303A (pt) Sistema de distrituição de droga termoformado, e, unidade de dosagem

Legal Events

Date Code Title Description
FG Grant, registration